Creso Pharma Ltd (CPH)
Company Deep Dive
Creso was created to bring pharmaceutical expertise and methodological rigour to the world of cannabis and deliver quality products to people and animals everywhere.
Founded by a team of highly-experienced pharmaceutical executives, Creso set out to leverage cutting edge science and research to develop, register and commercialise innovative cannabis and hemp derived products.
Some notable achievements:
The acquisition of Canadian psychedelics company Halucenex Life Sciences Inc. is now complete
Creso is the first ASX listed psychedelics company which gives it a first mover advantage
Psychedelic medicinal market estimated to be worth US $100bn by 2025
People
Board of Directors
Boaz Wachtel
Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company.
Boaz Wachtel
Director & Co-Founder
Mr. Wachtel is a leading Medical cannabis expert, co-founder and former managing director of Phytotech Medical (MMJ.ASX), Australia's first publically traded medical cannabis company. He initiated and helped implement the National Medical Cannabis Program in Israel. Mr. Wachtel is a certified Clinical research manager and holds an MA in management and marketing from the University of Maryland.
Adam Blumenthal
Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies.
Adam Blumenthal
Non-Executive Chairman & Co-Founder
Mr. Blumenthal has 10 years experience in investment banking and corporate finance. He has deep exposure to Australian and International markets, having provided capital raising and financing solutions to an extensive number of listed and unlisted companies. He has successfully brought to market several medical cannabis companies spanning Israel, Canada, Switzerland and Australia.
Dr. James Ellingford
Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA.
Dr. James Ellingford
Executive Director
Dr. Ellingford’s professional life culminated in being President of an international publicly listed billion dollar business with its headquarters in Geneva, Switzerland and New York, USA. He has vast experience in the international arena and has successfully developed close ties with both financial institutions as well as governments throughout the world.
Executives and Strategic Advisors
Jorge Wernli
Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups.
Jorge Wernli
Commercial/Market Access Director
Mr Wernli is an expert in Market Access, Pricing Reimbursement & Government Affairs with more than 30 years of experience in Big Pharmaceutical companies and start-ups. Previously he dealt with and built relationships with Ministries of Health in Europe, South America and selected Asian countries.
Dr. Gian Trepp
Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership.
Dr. Gian Trepp
Commercial/Marketing Director
Dr. Gian Trepp is a senior pharma marketing executive with over 18 years of strategic and operational leadership. He held worldwide executive leadership positions in General Management and Marketing within global pharmaceutical companies in Switzerland and in the US. He is the founder and owner of GBT Pharma, UK.
Chris Hession
Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region.
Chris Hession
Director of Strategic Partnerships
Mr. Hession brings over 20 years of commercial experience in the food, beverage and nutraceutical ingredients sectors across the APAC region. He has held leadership positions with a number of multi-national companies and introduced several new ingredients across the APAC region over this time.
Chris Grundy
Mr Grundy is a career CFO with over 30 years’ commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses.
Chris Grundy
Chief Financial Officer
Mr Grundy is a career CFO with over 30 years’ commercial experience in the life sciences sector, in listed and large multi- national companies as well as early-stage, rapidly-growing businesses. His experience in other companies includes operational roles in pharmaceutical manufacturing and distribution as CEO and in marketing. He has worked in Australia, the UK and Southern Africa. He qualified as a Chartered Accountant with Ernst & Young.
Bruce Linton
Mr. Linton is one of the world’s leading cannabis executives and an accomplished entrepreneur. He has extensive sector experience as a founder, CEO, Board member and adviser to a number of global cannabis companies.
Key Monetisation Avenues
Psychedelic Medicines
Creso Pharma recently completed its acquisition of Canadian psychedelics company Halucenex Life Sciences Inc. This landmark acquisition makes Creso the first ASX listed psychedelics company and provides a first mover advantage into the psychedelic medicine sector. In the near term, Halucenex will focus on progressing clinical trials to assess the safety and efficacy of using psilocybin to treat mental illness, with the aim of becoming a clinical drug pipeline provider. The company has already secured sufficient psilocybin to take the company up to conclusion of its Phase 3 Trial (March 2023), and will progress its Clinical Trial Application next month.
Psychedelic medicinal market estimated to be worth US $100bn by 2025
Psychedelics to Assist Mental Health
Studies have shown that psychedelics may be able to treat disorders such as depression, anxiety, and substance addiction. In clinical treatments, a patient receives a “microdose” of psilocybin to trigger the drug’s therapeutic benefits, without the disruptive effects seen at higher doses, such as hallucinations. The potential for psychedelic-assisted therapy to be commercialised as a safe and effective treatment provides a solution to the growing global mental health crisis.
California's "Bill SB 519" to Decriminalise Psychedelics
California has 39.5 million citizens. Bill SB 39 recently passed the State Assembly committee on Public Safety, and California is on track to become the second US state to legalise the use of psychedelics. If Bill SB 519 passes, the use and possession of psilocybin products will become legal.
This will be a positive result for Creso Pharma and Halucenex.
Medicinal Cannabis
Creso's goal has been to become the world’s most trusted supplier of cannabis and hemp derived products. The company can deliver products with standardized dosing and formulations through the application of pharmaceutical rigour, Good Manufacturing Practices (GMP) standards when appropriate and proprietary, innovative delivery technologies.
The product pipeline is extensive, with 2020 Q4 set to see a range of new products hit the market
USA Progressing Towards Federal Cannabis Legalisation
Legislation was introduced on 15 July to remove cannabis from the Controlled Substances Act and introduce regulations to tax cannabis. The Act allows cannabis companies to use the federal banking system. Creso has been preparing for the legislation for quite some time, getting its CBD products ready to enter US. Their 24,000 Square foot cultivation facility (“Mernova”) in Canada is located only 220 miles from the US border.
The US cannabis market is expected to reach a valuation of US$41Bn by 2024.
Key Milestones
Past Achievements
Upcoming Milestones
Investors and Capital Raises
Key Investors
S3 Consortium
Also known as “Stocks Digital”
Capital Raises
To undertake psychedelic clinical trials upon completion of the Halucenex transaction, and advance of nutraceutical products globally.
From institutional, professional, and sophisticated investors to repay debt, develop the Company’s business units in Canada and Switzerland, and accelerate growth.
From new and existing sophisticated and professional investors to accelerate growth across the human and animal health CBD product line.
News and Activities
Halucenex Secures Research Agreement with Acadia University
19 Sep 2021
Creso Pharma Pursues Dual NASDAQ Listing and Terminates RLH Merge
30 Aug 2021
Creso Pharma Completes the Acquisition of Halucenex
14 Jul 2021
Creso's Second Consecutive Quarter of Record Revenue Growth
30 Jun 2021